Abstract: Provided herein are T cell receptors (TCRs) or antigen-binding fragments thereof, such as those that recognize or bind a relatively hematopoietically-restricted minor histocompatibility antigen, e.g., HA-2. In particular, the present disclosure relates to TCRs that bind or recognize particular HA-2 peptides in the context of a major histocompatibility complex (MHC) molecule. The present disclosure further relates to nucleic acids encoding such TCRs, engineered cells comprising such TCRs, methods of isolating such TCRs, and uses thereof, for example, in cell therapy.

Abstract: Described are methods of manufacturing engineered T cells and methods of using the engineered T cells to treat hematological malignancies. The engineered T cells can be administered in combination with allogeneic stem cell transplant and reduce the need for prophylactic immunosuppression.

Abstract: This document provides methods and materials involved in cloning functional TCRs from single T cells. For example, methods and materials for obtaining nucleic acid encoding a TCR from a single T cell and arranging that nucleic acid to form nucleic acid vectors successfully designed to express a TCR, kits for obtaining nucleic acid encoding a TCR from a single T cell and arranging that nucleic acid to form nucleic acid vectors successfully designed to express a TCR, methods for making such kits, collections of nucleic acid primers designed to amplify the entire coding sequence of both variable regions for each expressed V segment for functional ?? or ?? TCRs of a particular mammalian species, methods for using such collections of nucleic acid primers to clone functional TCRs from single T cells, and kits containing such collections of nucleic acid primers to clone functional TCRs from single T cells are provided.

Abstract: This document provides methods and materials involved in cloning functional TCRs from single T cells. For example, methods and materials for obtaining nucleic acid encoding a TCR from a single T cell and arranging that nucleic acid to form nucleic acid vectors successfully designed to express a TCR, kits for obtaining nucleic acid encoding a TCR from a single T cell and arranging that nucleic acid to form nucleic acid vectors successfully designed to express a TCR, methods for making such kits, collections of nucleic acid primers designed to amplify the entire coding sequence of both variable regions for each expressed V segment for functional ?? or ?? TCRs of a particular mammalian species, methods for using such collections of nucleic acid primers to clone functional TCRs from single T cells, and kits containing such collections of nucleic acid primers to clone functional TCRs from single T cells are provided.

Abstract: This document provides methods and materials involved in cloning functional TCRs from single T cells. For example, methods and materials for obtaining nucleic acid encoding a TCR from a single T cell and arranging that nucleic acid to form nucleic acid vectors successfully designed to express a TCR, kits for obtaining nucleic acid encoding a TCR from a single T cell and arranging that nucleic acid to form nucleic acid vectors successfully designed to express a TCR, methods for making such kits, collections of nucleic acid primers designed to amplify the entire coding sequence of both variable regions for each expressed V segment for functional ?? or ?? TCRs of a particular mammalian species, methods for using such collections of nucleic acid primers to clone functional TCRs from single T cells, and kits containing such collections of nucleic acid primers to clone functional TCRs from single T cells are provided.

Abstract: The invention includes compositions and methods for depleting and/or inactivating antigen presenting cells, or for otherwise impairing the biological function of antigen presenting cells, which compositions are useful for treatment of graft versus host disease and other immune diseases.

Abstract: The present invention provides methods and compositions for treating immune complex associated diseases (ICAD), such as SLE, rheumatoid arthritis, and hepatitis-C related immune complex disease (e.g., cryoglobulinemia) in a subject having an ICAD or at risk for developing ICAD. The invention is based upon the surprising finding that chromatin-containing immune complexes activate autoreactive B cells and dendritic cells by a dual receptor engagement process which, in both cell types, involves a Toll-like receptor (TLR).